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Purpose: Accurate assessment of toxicity allows for timely delivery of supportive measures during
radiation therapy for head and neck cancer. The current paradigm requires weekly evaluation of
patients by a provider. The purpose of this study is to evaluate the feasibility of monitoring patient
reported symptoms via mobile devices.
Methods and materials: We developed a mobile application for patients to report symptoms in 5
domains using validated questions. Patients were asked to report symptoms using a mobile device
once daily during treatment or more often as needed. Clinicians reviewed patient-reported
symptoms during weekly symptom management visits and patients completed surveys regarding
perceptions of the utility of the mobile application. The primary outcome measure was patient
compliance with mobile device reporting. Compliance is deﬁned as number of days with a
symptom report divided by number of days on study.
Results: There were 921 symptom reports collected from 22 patients during treatment. Median
reporting compliance was 71% (interquartile range, 45%-80%). Median number of reports sub-
mitted per patient was 34 (interquartile range, 21-53). Median number of reports submitted byPresented in abstract form at the American Society of Clinical Oncology Annual Meeting, May 30, 2015, Chicago, IL.
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116 A.D. Falchook et al Advances in Radiation Oncology: AprileJune 2016patients per week was similar throughout radiation therapy and there was signiﬁcant reporting
during nonclinic hours. Patients reported high satisfaction with the use of mobile devices to report
symptoms.
Conclusions: A substantial percentage of patients used mobile devices to continuously report
symptoms throughout a course of radiation therapy for head and neck cancer. Future studies should
evaluate the impact of mobile device symptom reporting on improving patient outcomes.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Head and neck cancer patients receiving radiation
therapy often experience signiﬁcant toxicity. Common
side effects of head and neck radiation therapy include
mucositis, pain, xerostomia, nausea, vomiting, weight
loss, and fatigue. Monitoring patient symptoms during
radiation therapy is important because accurate assess-
ment of treatment toxicity allows for delivery of necessary
supportive measures. Clinician assessments of toxicity are
often discordant with patient-reported symptoms. One
cross-sectional study examining toxicity reporting
showed rates of discordance between clinician and patient
reported toxicity ranging between 15% and 59% for
various symptoms.1 Another study of patients enrolled in
clinical trials found that patient-reported toxicity was
higher than clinician-reported toxicity for a variety of
endpoints.2 Some evidence suggests that patient-reported
symptoms better correlate with underlying functional
status and clinical outcomes than clinician-reported
symptoms.3
Typically, patients receiving radiation therapy are
evaluated once per week by a health care provider during
a radiation treatment course. Although patients may report
symptoms to a physician or health care provider at any
time during treatment, it is common for symptoms to go
unreported until the weekly visit. This delay in reporting
of symptoms may lead to undertreatment of symptoms
or delay in diagnosis and management of toxicity.
Furthermore, evaluations of toxicity that are done peri-
odically (ie, weekly, monthly, or with each cycle of
chemotherapy) may be subject to recall bias and/or
underreporting of toxicity related to treatment. Increased
real-time reporting by patients may lead to improved
symptom ascertainment by providers. If patients report
symptoms immediately, this will provide the most accu-
rate representation of how patients are tolerating treat-
ment, which should allow providers to better manage
toxicity.
Internet-based patient-reported symptom assessment
has been reported for oncology and surgery patients, but
these studies did not speciﬁcally evaluate the use of
mobile device platforms.4,5 Mobile device ownership is
increasing, and reporting symptoms on a personal mobiledevice may be more convenient than using a computer to
access an Internet-based reporting system. We developed
a novel mobile application to allow patients to report
symptoms related to their treatment in real time. The
purpose of this study is to evaluate the feasibility of using
mobile device technology to continuously collect patient-
reported symptoms for head and neck cancer patients
receiving curative radiation therapy.
Methods
Patient selection
We conducted a single-institution prospective study to
evaluate the feasibility of using a mobile application to
allow head and neck cancer patients receiving curative
radiation therapy to report symptoms in real time.
This study was approved by the institutional review
board, and all patients provided written informed consent.
Enrollment was initiated in May 2014 and continued until
completion of patient accrual (December 2014). Eligi-
bility criteria included age 18 years with histologically
conﬁrmed T0-4 N0-3 M0 cancer of the head and neck.
Disease sites allowed were nasal cavity and sinuses,
nasopharynx, oropharynx, oral cavity, hypopharynx, lar-
ynx, salivary gland, and cutaneous malignancy. Patients
with early-stage larynx cancer treated with deﬁnitive
narrow-ﬁeld radiation therapy were ineligible because of
the low toxicity associated with this treatment.6 Planned
radiation dose was required to be 60 Gy (1.2-2.25 Gy/
fraction). All patients received either deﬁnitive (radiation
therapy as primary treatment) or postoperative radiation
therapy. Concurrent chemoradiation therapy was
permitted but not required. Patient performance status was
required to be 1 as measured by the Eastern Cooperative
Oncology Group Performance Status scale.7
Intervention
A Health Insurance Portability and Accountability
Actesecure mobile application was developed for
Android (Google Inc., Mountainview, CA) and iOS
(Apple Inc., Cupertino, CA) mobile operating systems.
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unique patient identiﬁcation number and password. No
patient-identifying information or protected health infor-
mation is transmitted by the application and therefore
there is no risk of compromise of protected health infor-
mation should an unauthorized person gain access to any
data transmitted by the application. The format of the data
transmitted to the server is a string consisting of 2 time-
stamps (indicating when patients opened the symptom-
reporting screen and when the symptom report was
submitted) as well as the numeric indices of patients’
answers to the symptom survey questions. The mobile
application was installed and initialized on patients’
smartphones and/or tablet computers by the study coor-
dinator. The study coordinator also provided instructions
to patients regarding use of the application. If patients did
not own a mobile device, a tablet computer was provided
by the clinic and returned after completion of the study.
The symptom-reporting application consists of a main
screen that indicates to patients whether or not they have
reported symptoms on the current date and displays the
time and date of the most recent symptom report.
A button entitled “Report My Symptoms” opens a screen,
which allows patients to report symptom severity in 5
domains (fatigue, pain, nausea/vomiting, decreased
appetite, anxiety) using questions adapted from the Pa-
tient Reported Symptom Monitoring System, a validated
instrument to measure toxicity (other data; A. M. Stover,Figure 1 Mobile application screenshots, showing the mainet al., unpublished data). For each domain, patients could
report toxicity as follows: none, mild, moderate, severe,
or very severe. Patients were asked to report symptoms
using a smartphone and/or tablet at least once daily
(including weekends) during treatment and encouraged to
report multiple times daily as symptoms were occurring.
The mobile application also provides a button to allow
patients to call the clinic directly (not available for tablet
computers). The application interface is shown in Fig 1.
To ensure that the application was nonintrusive, there
were no mobile-device notiﬁcations or other reminders to
prompt patient reporting of symptoms. Patients were
instructed that symptoms would not be immediately seen
by the clinician in a timely manner, but would be
reviewed retrospectively during the weekly clinical visit.
The typical radiation therapy treatment course for head
and neck cancer is once or twice daily, Monday through
Friday for a total of 25 to 35 treatment days (approxi-
mately 5 to 7 weeks). As part of routine clinical practice,
patients are seen by clinicians once weekly during treat-
ment to manage treatment-related toxicity/symptoms. At
the end of the visit, providers reviewed the patient-
reported data with patients. Clinical impact of patient-
reported symptoms on toxicity management and patient
outcomes is not reported in this feasibility study, but data
were collected for future analysis. Patient surveys
regarding use of mobile devices were obtained before and
after completion of radiation therapy. Patients alsoscreen (left) and survey screen (right) of the application.
Table 1 Patient demographics and treatment
characteristics
Characteristic N %
Patient
characteristics
Sex
Male 15 68
Female 7 32
Age (y)
<60 13 59
60 9 41
Marital status
Married 16 73
Not married 6 27
Race
White 18 82
Black 4 18
College or advanced
degree
No 14 64
Yes 8 36
Insurance coverage
No 5 23
Yes 17 77
Household income
<$70,000 11 50
$70,000 11 50
Disease site
Oropharynx 9 41
Sinonasal 4 18
Oral cavity 3 14
Unknown primary 2 9
Othera 4 18
Treatment
characteristics
Concurrent
chemotherapy
Yes 18 82
No 4 18
Radiation therapy
course
Deﬁnitive 13 59
Postoperative 9 31
Radiation therapy
technique
IMRT 21 95
Conformal 1 5
Median IQR
Radiation therapy
prescription dose
(Gy)
69.6 60-70
Radiation therapy
treatment duration
(d)
45.5 42-49
IMRT, intensity modulated radiation therapy; IQR, interquartile
range.
a Other includes larynx, skin, nasopharynx, and cervical
esophagus.
118 A.D. Falchook et al Advances in Radiation Oncology: AprileJune 2016completed a survey to provide demographic information,
such as race and income.
Outcome measures
The primary endpoint of this study was patient
reporting compliance, which is deﬁned as the number of
days with any patient report submitted divided by the
number of days between day 1 of treatment and the end
of radiation therapy. A prespeciﬁed deﬁnition of feasi-
bility is that at least 80% of patients use the application at
least 80% of the days during radiation treatment. Patient
survey responses regarding mobile device use were a
secondary endpoint of this study. We also report total
number of symptom reports submitted per patient, timing
of report submissions, and time required for patients to
complete and submit the symptom survey using mobile
devices.
Statistical analysis
Descriptive statistics summarize patient demographics,
treatment characteristics, patterns of use for the mobile
application, and survey responses. A study sample size of
20 patients allows the proportion of patients who
demonstrate reporting compliance of at least 80% to be
estimated within 23% (using an exact 95% conﬁdence
interval). All statistical analyses were performed using
SAS, version 9.4 (SAS Institute, Cary, NC).
Results
Fifty-ﬁve patients were eligible for enrollment, of
which 22 (40%) were accrued and included in this anal-
ysis. Reasons for nonenrollment of eligible patients
included: patient did not own a mobile device and no
tablet was available to loan from clinic (20 patients),
enrollment on a different clinical trial (6 patients),
homelessness (2 patients), and unknown (5 patients). One
patient withdrew consent during treatment for unknown
reasons; data collected from this patient before with-
drawal of consent were included for analysis. One patient
was ineligible because of disease site (cervical esophagus)
and dose (50.4 Gy); data collected from this patient were
included in analysis of application feasibility. Patient
demographics and treatment characteristics are shown in
Table 1.
Patient symptom reporting
Patient compliance and the total number of reports
submitted are shown in Fig 2. Median reporting
compliance was 71% (interquartile range [IQR], 45%-
80%). Six patients (27%) demonstrated reportingcompliance 80% and 2 patients (9%) were 100%
compliant. The median number of reports submitted per
patient was 34 (IQR, 21-53).
Figure 2 Reporting compliance and number of reports submitted, per patient. Reporting compliance is deﬁned as the number of days
with any patient reported symptom divided by the number of days between study enrollment and the end of radiation therapy.
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tion is reported in Table 2. Mobile application use was
consistent during all days of the week and symptom
reporting did not decrease during the later weeks of
treatment. Five hundred and sixteen (56%) of all patient
reports were submitted during nonclinic hours (5 PM-7
AM or weekends). The median time between opening
the symptom-reporting screen and pressing the submitTable 2 Timing of symptom reporting using the mobile
application
Reports per
patient (median)
IQR
Day of week
Sun 5 3-7
Mon 5 3-8
Tue 5 4-8
Wed 5 3-8
Thurs 5.5 4-7
Fri 6 3-10
Sat 4 2-6
Week of treatment
1 7 3-10
2 6 5-7
3 6 5-9
4 6.5 4-9
5 6 4-8
6 5 3-7
7 6.5 5-12
Report during clinic hours
(7 AM-5 PM,
weekdays)
Nonclinic hours 17 10-30
Clinic hours 14.5 9.5-27.5
IQR, interquartile range.button was 22 seconds (IQR, 15-35). Ninety-ﬁve percent
of all symptom reports required 150 seconds or less to
submit using the application. Subgroup analysis of reports
in which any symptom was reported as severe or very
severe (N Z 209) demonstrated median time to report of
24 seconds (IQR, 17-43).
Patient satisfaction with using mobile devices to report
symptoms was high and overall pretreatment and post-
treatment survey responses were positive (Table 3).
Posttreatment survey data were available for 19 of the 21
patients who completed the study (90%). One hundred
percent of respondents reported that participating in the
trial was worthwhile and that they would recommend to
others to participate in similar trials evaluating the use of
mobile device technology.Discussion
This study demonstrates that substantial symptom
reporting is possible using mobile device technology. The
prespeciﬁed deﬁnition of feasibility, which required 80%
of patients to report symptoms with 80% compliance,
may have been an unrealistically high bar. Although this
endpoint was not met, the signiﬁcant levels of patient
reporting observed in this study are encouraging and
suggest that mobile devices can be a useful method to
collect patient-reported outcomes. This study population
was diverse with respect to race, age, gender, and other
sociodemographic variables and is representative of the
head and neck cancer population treated at our institution.
Previous studies evaluating mobile device symptom
reporting for patients receiving chemotherapy experi-
enced a steady decline in participants contributing data.8
Similarly, a study demonstrating feasibility of using
Table 3 Summary of pretreatment survey and posttreat-
ment survey responses
Response N %
Pretreatment survey questions
Reporting treatment side
effects daily will help my
physician better manage my
symptoms
Agree 13 59
Strongly
agree
9 41
I am conﬁdent that it will be
easy to use the application to
report symptoms daily
Agree 13 59
Strongly
agree
9 41
I am conﬁdent that I will report
symptoms at least once per
day, and more often as
needed
Neutral 1 5
Agree 12 55
Strongly
agree
9 41
I feel comfortable using my
smartphone or tablet to
report symptoms to my
physician
Agree 13 59
Strongly
agree
9 41
The most accurate and
convenient way to record
symptoms on a daily basis is
Smartphone
or tablet
22 100
Internet Web
site
0 0
Paper survey 0 0
Posttreatment survey questions
Reporting treatment side
effects on a daily basis
helped my physician to
better manage my symptoms
Agree 11 58
Strongly
agree
8 42
I found it convenient to use the
application to report
symptoms daily
Disagree 1 5
Neutral 2 11
Agree 8 42
Strongly
agree
8 42
I felt comfortable using a
smartphone or tablet to
report symptoms to my
physician
Agree 10 53
Strongly
agree
9 47
What type of mobile device
did you most frequently use
to submit your daily
symptoms
Smartphone 7 37
Tablet
computer
12 63
Who reported your symptoms
most of the time?
Patient 16 84
Caregiver 2 11
Both patient
and
caregiver
1 5
The most accurate and
convenient way to record
symptoms on a daily basis is
Smartphone
or tablet
17 89
Internet Web
site
1 5
Paper survey 1 5
I felt that participating in this
trial was worthwhile
True 19 100
False 0 0
I would recommend to other
people that they participate
in this trial
True 19 100
False 0 0
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from patients receiving radiation therapy for head and
neck cancer showed a reduction in survey completion at
later follow-up visits.9 In contrast, the present study
demonstrated a high level of patient reporting throughout
the completion of therapy, and we did not observe
reductions in reporting compliance during later weeks of
treatment.
Head and neck cancer patients are commonly treated
with multimodality therapy that is associated with sub-
stantial toxicity and high rates of unplanned hospital
admission.10 This patient population could therefore
experience a signiﬁcant beneﬁt from aggressive symptom
management facilitated by the use of mobile device
technology.
Toxicity from radiation therapy increases throughout
treatment, with minimal toxicity in the ﬁrst 1-2 weeks and
increasing toxicity in later weeks of treatment. This study
demonstrated that mobile application symptom reporting
can be used to collect data from patients even as they
experience signiﬁcant toxicity later in treatment. When
analysis was restricted to only reports that contained at
least 1 domain with severe or very severe symptoms,
patients demonstrated an ability to quickly report symp-
toms. This may be due to the fact that mobile devices are
easily accessible at short notice compared with other
forms of symptom reporting. Furthermore, the design of
this application did not require patients to log in with a
username and password, which may have expedited
patient reporting. The high level of patient reporting on
nights and weekends is indicative that patients are willing
to use mobile applications continuously to report symp-
toms as they occur, which can help eliminate issues
related to recall when assessing toxicity. Given this high
level of continuous reporting, data collected from mobile
devices may provide a more complete picture of toxicity
experienced by patients during treatment.
An important ﬁnding of this study is that even the least
compliant patients provided a substantial number of
symptom reports. The average number of total symptom
reports submitted by the least compliant quartile of
patients was 18 reports. In the absence of mobile devi-
ceebased symptom reporting, these patients would typi-
cally have reported symptoms only once weekly
(typically 6-7 times) during their course of radiation
therapy. Therefore, the mobile application allowed for
symptom reporting at least 3 times more often than would
otherwise have been achieved.
A potential limitation of this study is that enrollment
may have been higher among patients more likely to
demonstrate willingness and ability to use mobile device
technology to communicate symptoms. Approximately
60% of potentially eligible patients were not enrolled on
this study. It is notable that, among these patients, 61%
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device and lack of availability of a tablet to loan from the
clinic. In the present study, no differences were seen in
symptom reporting for patients who used their own de-
vice versus a clinic-provided tablet. Enrollment of pa-
tients was more likely limited by a lack of availability of
tablets to loan rather than selection of only the most
willing patients to participate. It is true that mobile-based
symptom reporting will not be feasible for all patients,
but this should not preclude us from offering this tech-
nology whenever possible to patients who could poten-
tially beneﬁt. Novel techniques and creative approaches
are required to facilitate symptom reporting for patients
who are less likely to use mobile device technology.
All patients in the present study were treated with
curative intent. There is an opportunity to use mobile
device technology to improve delivery of care for patients
with metastatic cancer as well. Issues related to symptom
management are different for patients receiving palliative
radiation therapy. Doses of radiation prescribed for these
patients are generally much lower than curative-intent
cases and toxicity is typically more attributable to disease
progression than treatment. Also, acuity of illness may be
higher among patients with metastatic disease. Metastatic
patients may beneﬁt from rigorous symptom assessment
to prevent unplanned admissions and maximize efforts to
provide palliative care. Additional study is needed to
determine if it is feasible to use mobile device technology
to improve symptoms and minimize toxicity for patients
with metastatic disease.
Future Directions/Conclusions
A substantial percentage of patients used mobile de-
vices to continuously report symptoms throughout a
course of radiation therapy for head and neck cancer.
Electronic symptom reporting is emerging as a potentially
powerful tool to improve the quality of health care.11 Pilot
trials have demonstrated that patients are willing and able
to report their own symptomatic toxicity in clinical
trials.12 Patient-directed continuous self-reporting of
symptoms is a method to improve accuracy of toxicity
assessment in the setting of clinical trials.13
With continuous patient reporting of symptoms, the
kinetics of patient reporting (by time, severity, frequency,
etc.) can be studied and may be indicative or predictive of
an impending clinical event (eg, hospital admission,
urgent clinic visits). Earlier interventions may prevent
escalation of symptoms and prevent hospital admission.The mobile application evaluated in this study is currently
being used as part of a pilot study to reduce the rate of
unplanned hospital admissions for high-risk patients
receiving radiation therapy through intensive symptom
management during treatment.
References
1. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician
symptom reporting using the National Cancer Institute Common
Terminology Criteria for Adverse Events: Results of a
questionnaire-based study. Lancet Oncol. 2006;7:903-909.
2. Basch E. The missing voice of patients in drug-safety reporting.
N Engl J Med. 2010;362:865-869.
3. Basch E, Jia XY, Heller G, et al. Adverse symptom event reporting
by patients vs clinicians: Relationships with clinical outcomes. J Nat
Cancer Inst. 2009;101:1624-1632.
4. Basch EM, Reeve BB, Mitchell SA, et al. Electronic toxicity
monitoring and patient-reported outcomes. Cancer J. 2011;17:
231-234.
5. Andikyan V, Rezk Y, Einstein MH, et al. A prospective study of
the feasibility and acceptability of a Web-based, electronic
patient-reported outcome system in assessing patient recovery
after major gynecologic cancer surgery. Gynecol Oncol. 2012;
127:273-277.
6. Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M.
Radiotherapy for early glottic carcinoma (T1N0M0): Results of
prospective randomized study of radiation fraction size and overall
treatment time. Int J Radiat Oncol Biol Phys. 2006;64:77-82.
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 1982;5:649-655.
8. Kearney N, McCann L, Norrie J, et al. Evaluation of a mobile
phone-based, advanced symptom management system (ASyMS) in
the management of chemotherapy-related toxicity. Support Care
Cancer. 2009;17:437-444.
9. Pollom EL, Wang E, Bui TT, et al. A prospective study of electronic
quality of life assessment using tablet devices during and after
treatment of head and neck cancers. Oral Oncol. 2015;51:1132-
1137.
10. Waddle MR, Chen RC, Arastu NH, et al. Unanticipated hospital
admissions during or soon after radiation therapy: Incidence and
predictive factors. Pract Radiat Oncol. 2015;5:e245-e253.
11. Johansen MA, Henriksen E, Horsch A, Schuster T, Berntsen GK.
Electronic symptom reporting between patient and provider for
improved health care service quality: A systematic review of ran-
domized controlled trials. Part 1: State of the art. J Med Internet Res.
2012;14:e118.
12. Pietanza MC, Basch EM, Lash A, et al. Harnessing technology to
improve clinical trials: Study of real-time informatics to collect
data, toxicities, image response assessments, and patient-reported
outcomes in a phase II clinical trial. J Clin Oncol. 2013;31:
2004-2009.
13. Ahmed S, Berzon RA, Revicki DA, et al. The use of patient-
reported outcomes (PRO) within comparative effectiveness
research implications for clinical practice and health care policy.
Med Care. 2012;50:1060-1070.
